Antibody;1MG;IgM/kappa;This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is deteced with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.;Anti-SARS-CoV-2 Spike RBD Neutralizing antibody, Human IgM (SPD-M162) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293).; The protein migrates as 62.6 kDa and 23.5 kDa under reducing (R) condition (SDS-PAGE).;Immobilized Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (Cat. No. SPD-M162) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H1) with a linear range of 0.6-2.4 ng/mL (QC tested).;Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (Cat. No. SPD-M162) was detected by Biotinylated Human ACE2, His,Avitag (Cat. No. AC2-H82E6) with a half maximal inhibitory con